Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51.

ABSTRACT:

Background

Chagas Disease, a WHO- and NIH-designated neglected tropical disease, is endemic in Latin America and an emerging infection in North America and Europe as a result of population moves. Although a major cause of morbidity and mortality due to heart failure, as well as inflicting a heavy economic burden in affected regions, Chagas Disease elicits scant notice from the pharmaceutical industry because of adverse economic incentives. The discovery and development of new routes to chemotherapy for Chagas Disease is a clear priority.

Methodology/principal findings

The similarity between the membrane sterol requirements of pathogenic fungi and those of the parasitic protozoon Trypanosoma cruzi, the causative agent of Chagas human cardiopathy, has led to repurposing anti-f

SUBMITTER: Gunatilleke SS 

PROVIDER: S-EPMC3409115 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature